|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BDKRB1 |
Gene summary for BDKRB1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BDKRB1 | Gene ID | 623 |
| Gene name | bradykinin receptor B1 | |
| Gene Alias | B1BKR | |
| Cytomap | 14q32.2 | |
| Gene Type | protein-coding | GO ID | GO:0001558 | UniProtAcc | P46663 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 623 | BDKRB1 | P11T-E | Human | Esophagus | ESCC | 9.72e-03 | 7.40e-01 | 0.1426 |
| 623 | BDKRB1 | P21T-E | Human | Esophagus | ESCC | 2.95e-11 | 3.37e-01 | 0.1617 |
| 623 | BDKRB1 | P22T-E | Human | Esophagus | ESCC | 3.85e-02 | 1.59e-01 | 0.1236 |
| 623 | BDKRB1 | P36T-E | Human | Esophagus | ESCC | 8.77e-03 | 3.32e-01 | 0.1187 |
| 623 | BDKRB1 | P37T-E | Human | Esophagus | ESCC | 1.63e-02 | 6.92e-02 | 0.1371 |
| 623 | BDKRB1 | P47T-E | Human | Esophagus | ESCC | 5.24e-06 | 1.24e-01 | 0.1067 |
| 623 | BDKRB1 | P62T-E | Human | Esophagus | ESCC | 2.82e-04 | 2.15e-01 | 0.1302 |
| 623 | BDKRB1 | P65T-E | Human | Esophagus | ESCC | 1.04e-03 | -2.46e-02 | 0.0978 |
| 623 | BDKRB1 | P80T-E | Human | Esophagus | ESCC | 1.67e-08 | 5.95e-01 | 0.155 |
| 623 | BDKRB1 | P83T-E | Human | Esophagus | ESCC | 3.43e-19 | 8.97e-01 | 0.1738 |
| 623 | BDKRB1 | P89T-E | Human | Esophagus | ESCC | 3.93e-05 | 1.14e+00 | 0.1752 |
| 623 | BDKRB1 | P91T-E | Human | Esophagus | ESCC | 6.50e-06 | 9.26e-01 | 0.1828 |
| 623 | BDKRB1 | P127T-E | Human | Esophagus | ESCC | 7.30e-04 | -1.76e-02 | 0.0826 |
| 623 | BDKRB1 | C04 | Human | Oral cavity | OSCC | 1.20e-16 | 8.70e-01 | 0.2633 |
| 623 | BDKRB1 | C21 | Human | Oral cavity | OSCC | 9.65e-04 | 3.92e-01 | 0.2678 |
| 623 | BDKRB1 | C30 | Human | Oral cavity | OSCC | 3.81e-14 | 7.83e-01 | 0.3055 |
| 623 | BDKRB1 | C43 | Human | Oral cavity | OSCC | 6.18e-22 | 5.71e-01 | 0.1704 |
| 623 | BDKRB1 | SYSMH2 | Human | Oral cavity | OSCC | 2.54e-17 | 4.19e-01 | 0.2326 |
| 623 | BDKRB1 | SYSMH3 | Human | Oral cavity | OSCC | 2.69e-14 | 3.53e-01 | 0.2442 |
| 623 | BDKRB1 | SYSMH4 | Human | Oral cavity | OSCC | 5.48e-08 | 2.21e-01 | 0.1226 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010563111 | Esophagus | ESCC | negative regulation of phosphorus metabolic process | 274/8552 | 442/18723 | 2.32e-12 | 9.41e-11 | 274 |
| GO:0045936111 | Esophagus | ESCC | negative regulation of phosphate metabolic process | 273/8552 | 441/18723 | 3.18e-12 | 1.25e-10 | 273 |
| GO:0016049110 | Esophagus | ESCC | cell growth | 289/8552 | 482/18723 | 1.29e-10 | 3.77e-09 | 289 |
| GO:0042326111 | Esophagus | ESCC | negative regulation of phosphorylation | 237/8552 | 385/18723 | 1.86e-10 | 5.33e-09 | 237 |
| GO:0001933111 | Esophagus | ESCC | negative regulation of protein phosphorylation | 213/8552 | 342/18723 | 3.54e-10 | 9.76e-09 | 213 |
| GO:000155819 | Esophagus | ESCC | regulation of cell growth | 248/8552 | 414/18723 | 2.97e-09 | 6.45e-08 | 248 |
| GO:0051235110 | Esophagus | ESCC | maintenance of location | 200/8552 | 327/18723 | 1.01e-08 | 2.02e-07 | 200 |
| GO:00459267 | Esophagus | ESCC | negative regulation of growth | 148/8552 | 249/18723 | 7.88e-06 | 7.73e-05 | 148 |
| GO:0051651111 | Esophagus | ESCC | maintenance of location in cell | 126/8552 | 214/18723 | 6.57e-05 | 5.00e-04 | 126 |
| GO:003249619 | Esophagus | ESCC | response to lipopolysaccharide | 191/8552 | 343/18723 | 1.11e-04 | 7.73e-04 | 191 |
| GO:000961216 | Esophagus | ESCC | response to mechanical stimulus | 124/8552 | 216/18723 | 3.30e-04 | 1.94e-03 | 124 |
| GO:00303085 | Esophagus | ESCC | negative regulation of cell growth | 108/8552 | 188/18723 | 7.46e-04 | 3.87e-03 | 108 |
| GO:000223719 | Esophagus | ESCC | response to molecule of bacterial origin | 194/8552 | 363/18723 | 1.64e-03 | 7.61e-03 | 194 |
| GO:000268515 | Esophagus | ESCC | regulation of leukocyte migration | 114/8552 | 210/18723 | 7.26e-03 | 2.63e-02 | 114 |
| GO:001604917 | Oral cavity | OSCC | cell growth | 268/7305 | 482/18723 | 6.55e-14 | 3.51e-12 | 268 |
| GO:001056320 | Oral cavity | OSCC | negative regulation of phosphorus metabolic process | 246/7305 | 442/18723 | 6.12e-13 | 2.89e-11 | 246 |
| GO:004593620 | Oral cavity | OSCC | negative regulation of phosphate metabolic process | 245/7305 | 441/18723 | 8.85e-13 | 4.09e-11 | 245 |
| GO:000155816 | Oral cavity | OSCC | regulation of cell growth | 228/7305 | 414/18723 | 1.74e-11 | 6.09e-10 | 228 |
| GO:004232619 | Oral cavity | OSCC | negative regulation of phosphorylation | 214/7305 | 385/18723 | 2.30e-11 | 7.74e-10 | 214 |
| GO:000193319 | Oral cavity | OSCC | negative regulation of protein phosphorylation | 191/7305 | 342/18723 | 1.58e-10 | 4.62e-09 | 191 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0481028 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
| hsa04810112 | Esophagus | ESCC | Regulation of actin cytoskeleton | 133/4205 | 229/8465 | 5.94e-03 | 1.48e-02 | 7.56e-03 | 133 |
| hsa0481026 | Oral cavity | OSCC | Regulation of actin cytoskeleton | 129/3704 | 229/8465 | 7.14e-05 | 2.74e-04 | 1.40e-04 | 129 |
| hsa04810111 | Oral cavity | OSCC | Regulation of actin cytoskeleton | 129/3704 | 229/8465 | 7.14e-05 | 2.74e-04 | 1.40e-04 | 129 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BDKRB1 | SNV | Missense_Mutation | rs747328339 | c.689N>A | p.Arg230Gln | p.R230Q | P46663 | protein_coding | tolerated(0.15) | possibly_damaging(0.595) | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| BDKRB1 | SNV | Missense_Mutation | c.315N>G | p.Phe105Leu | p.F105L | P46663 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| BDKRB1 | SNV | Missense_Mutation | c.8C>T | p.Ser3Leu | p.S3L | P46663 | protein_coding | deleterious_low_confidence(0.03) | benign(0) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| BDKRB1 | SNV | Missense_Mutation | novel | c.1025A>G | p.His342Arg | p.H342R | P46663 | protein_coding | tolerated(0.71) | benign(0) | TCGA-E2-A2P5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | PD |
| BDKRB1 | SNV | Missense_Mutation | novel | c.617N>C | p.Leu206Ser | p.L206S | P46663 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-GM-A2DN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
| BDKRB1 | SNV | Missense_Mutation | rs371690606 | c.694N>T | p.Arg232Trp | p.R232W | P46663 | protein_coding | deleterious(0.04) | probably_damaging(0.987) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| BDKRB1 | SNV | Missense_Mutation | rs780064132 | c.167N>C | p.Leu56Pro | p.L56P | P46663 | protein_coding | deleterious(0.01) | possibly_damaging(0.878) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| BDKRB1 | SNV | Missense_Mutation | novel | c.1021N>A | p.Ser341Thr | p.S341T | P46663 | protein_coding | tolerated(0.31) | benign(0.2) | TCGA-MA-AA43-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| BDKRB1 | SNV | Missense_Mutation | novel | c.893N>C | p.Asn298Thr | p.N298T | P46663 | protein_coding | tolerated(0.6) | benign(0.007) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
| BDKRB1 | SNV | Missense_Mutation | novel | c.1002N>G | p.Ser334Arg | p.S334R | P46663 | protein_coding | tolerated(0.34) | benign(0) | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 623 | BDKRB1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | CHEMBL3545386 | BI113823 | |
| 623 | BDKRB1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 135652338 | ||
| 623 | BDKRB1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | Safotibant | SAFOTIBANT | ||
| 623 | BDKRB1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 135650120 | ||
| 623 | BDKRB1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 135651895 | ||
| 623 | BDKRB1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 135652108 | ||
| 623 | BDKRB1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 135652006 | ||
| 623 | BDKRB1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 135650752 | ||
| 623 | BDKRB1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 135651731 | ||
| 623 | BDKRB1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 135652008 |
| Page: 1 2 3 4 5 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |